Table 5. Cox proportional hazard model for OS in KRAS wild-type mCRC patients.

	Univariate analysis			Multivariate analysis
Variable	HR1	95%CI2	P	HR	95%CI	P
Age			0.29			0.92
≥65	1.22	0.85–1.75		0.98	0.66–1.45
<65	1.00			1.00
Sex			0.97			0.74
Female	1.00	0.69–1.47		0.93	0.61–1.42
Male	1.00			1.00
Initial Dx as stage IV						0.14
Yes	1.10	0.74–1.63	0.63	1.94	0.81–4.65
No	1.00			1.00
Primary site
Distal	0.88	0.59–1.31	0.52	0.84	0.55–1.28	0.41
Proximal	1.00			1.00
Cetuximab			0.0001			0.02
Never-used	1.98	1.36–2.89		1.61	1.07–2.4
Had been used	1.00			1.00
Oxaliplatin
Never-used	1.37	0.79–2.37	0.26	1.12	0.62–2.02	0.7
Had been used	1.00			1.00
Irinotecan
Never-used	2.49	1.63–3.83	0.0001	1.99	1.25–3.19	0.004
Had been used	1.00			1.00
Bevacizumab
Never-used	1.26	0.88–1.82	0.21	1.06	0.72–1.55	0.78
Had been used	1.00			1.00
Chemotherapy in stage III
No	1.02	0.67–1.54	0.93	0.54	0.22–1.36	0.18
Yes	1.00			1.00
No. of mets
1	0.64	0.43–0.96	0.03	0.75	0.49–1.15	0.18
≥2	1.00			1.00

¹HR: hazard ratio. ²CI: confidence interval.